ArticleFrontiers in endocrinology2026
Cushing syndrome of different etiologies - cardiometabolic complications, venous thromboembolic events and mortality: data from ERCUSYN Krakow database.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hypercortisolism: Causes, Consequences and Clinical Significance - A Review of Pathophysiology.Diabetes, obesity & metabolism · 2026Review
- Individualized osilodrostat treatment for patients with ACTH-dependent Cushing's syndrome: real-world evidence.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cushing syndrome (CS) as a state of prolonged cortisol excess is associated with multiple complications that contribute to increased mortality in affected patients. Materials and methodology: This retrospective study presents data on etiology, demographic features, baseline cardiometabolic comorbidities, venous thromboembolic events and mortality of 214 consecutive CS patients from a single tertiary endocrinology center in Poland, a part of the European Register on Cushing's Syndrome (ERCUSYN). The group was predominated by pituitary CS (53%, PIT-CS), followed by adrenal CS (25%, ADR-CS) and ectopic CS (22%, ECT-CS). Statistica 13.0 was used to perform data analysis. Statistical significance was settled for a p-value ≤0.05. Results: The PIT-CS group was significantly younger than others. The PIT-CS and ADR-CS groups were predominated by women, contrary to the ECT-CS group, predominated by men. At the baseline, respectively 80%, 78%, and 66% of patients presented hypertension, dyslipidemia, and glucose metabolism impairments. Ischemic heart disease and heart failure were significantly more prevalent among ECT-CS. Venous thromboembolic events were present among 6% of patients. Overall mortality rate was 18%, and was higher in males than females (30% vs 15%; p<0.05), and was the highest in ECT-CS group (62%). The most common cause of death was tumor progression (55%) and infectious disease (26%). Conclusions: CS patients from our study presented a high number of comorbidities and high mortality rate. Some of the results were convergent with reports of the entire ERCUSYN database and other studies, while other results differed from the data reported in the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.